Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

Research and Markets has announced the addition of John Wiley and Sons Ltd's new book "Monoclonal Antibody and Peptide-Targeted Radiotherapy of Cancer" to their offering.

Targeted radiotherapy relies on and exploits characteristics of cancer cells to attack tumors. Monoclonal Antibody and Peptide-Targeted Radiotherapy of Cancer helps readers understand this hot pharmaceutical field with up-to-date developments. Expert discussion covers a range of diverse topics associated with this field, including the optimization of design of biomolecules and radiochemistry, cell and animal models for preclinical evaluation, discoveries from key clinical trials, radiation biology and dosimetry, and considerations in regulatory approval. With chapters authored by internationally renowned experts, this book delivers a wealth of information to push future discovery.

This book constitutes an expert discussion of the diverse aspects of monoclonal antibody and peptide-targeted radiotherapy of cancer. The chapters cover topics ranging from the optimization of design of biomolecules and radiochemistry, cell and animal models for preclinical evaluation, discoveries from key clinical trials , radiation biology and dosimetry, considerations in regulatory approval, as well as health economics issues that need to be appreciated to ultimately see their widespread use in clinical oncology. New and emerging areas such as molecular imaging in evaluating the response and resistance to targeted radiotherapy, a discussion of the bystander effect which may enhance its effectiveness, and the potential of combining cytolytic virus therapy with targeted radiotherapy have also been included. Many chapters are authored by internationally reknowned experts who have made the seminal discoveries in the field and by others who are leaders in areas that will be important to its future.

"This excellent book covers the whole field of targeted radionuclide therapy. The book includes choice of targeting agents and radionuclides, radiochemistry and radiolabeling, dosimetry, good coverage of medical aspects on selected tumor types (e.g. CNS tumors, neuroendocrine tumors, lymphomas and leukemias) and some aspects on relevant biological processes. Internationally well-recognized scientists have written the chapters. The book is unique thanks to chapters on viral introduction of receptors for radionuclide targeting, suitable tumor models, economy of targeted radionuclide therapy and regulatory matters. One aspect that strongly speaks in favor for this book is that targeted radionuclide therapy is an interesting and probably in many cases necessary complement or alternative to chemotherapy, especially when the cancer cells have gained multidrug resistance.... The book is suitable for PhD students in the field, for medical doctors in nuclear medicine and for all persons in the medical field that looks for new avenues to more effective killing of cancer cells.... It is an excellent written and up-to date introduction to the field of targeted radionuclide therapy of cancer and the book is strongly recommended to interested readers."

Source: Research and Markets